|Bid||50.00 x 800|
|Ask||50.50 x 900|
|Day's Range||49.29 - 50.18|
|52 Week Range||24.62 - 61.57|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||1,298.42|
|Earnings Date||May 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||63.20|
"I like it and I'd be a buyer," said Cramer of the cancer diagnostics and pharma services firm. The On-Balance-Volume (OBV) line has been strong and has gone up to new highs foreshadowing further price gains, in my opinion. The OBV line has been positive for the past three years and the MACD oscillator is pointed down but narrowing.
MYERS, FL / ACCESSWIRE / April 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the 20th Annual Needham Virtual Healthcare Conference 2021, on Thursday, April 15, 2021 at 11:00am ET.
FT MYERS, FL / ACCESSWIRE / April 7, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its first quarter 2021, financial results on Wednesday, May 5, 2021.